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Abstract
Purpose The current article looks at some of the factors
associated with pituitary adenomas displaying unusually
aggressive biological and clinical behaviour in patients
with acromegaly.
Methods This was a retrospective, narrative review of
previously published evidence chosen at the authors’ dis-
cretion and presented from the perspective of a Latin
American case study.
Findings and Conclusions Although most pituitary
tumors in acromegalic patients are benign and non-
aggressive many can behave more aggressively, compro-
mising local surrounding structures. These lesions tend to
respond poorly to somatostatin analogs, have a higher risk
of recurrence after surgery and, thus, a worse prognosis.
Patients with more aggressive tumors constitute a particu-
lar challenge, as they often require several therapeutic
approaches and may be difficult to manage, especially
when options are restricted due to limited resources.
Keywords Acromegaly  GH  IGF-1  Aggressive
tumors  Somatostatin analogs  Dopamine agonists
Introduction
Most pituitary tumors in acromegalic patients are benign
and respond well to multimodal therapy [1]. Nevertheless,
many pituitary adenomas can behave in a more aggressive
manner, with more rapid growth, local invasion into the
surrounding structures, greater risk of recurrence after
surgery and worse prognosis [1–3]. Patients with invasive
and more aggressive GH-secreting tumors often require
several therapeutic approaches and may be difficult to
manage [1], especially when options are restricted due to
limited resources. The current article presents a case report
of a somatotropic tumor with aggressive behavior and
discusses some of the treatment challenges and difficult
choices that this can impose in Latin America.
What defines an aggressive tumor in acromegaly?
Tumor aggressiveness can be based on clinical, radiologi-
cal and pathological features. However, there are no well-
defined absolute criteria for defining an aggressive pituitary
tumor. The 2004 World Health Organization classification
of pituitary tumors defined three primary types—‘‘typical
pituitary adenoma’’, ‘‘atypical pituitary adenoma’’ and
‘‘pituitary carcinoma’’ [4, 5]. The rather poorly defined
‘‘atypical’’ designation was an attempt to identify those
adenomas that are likely to display more aggressive
behavior with increased proliferative activity. The specific
‘‘atypical’’ characteristics that were identified included
invasion into the cavernous sinuses, an elevated prolifera-
tion index [Ki-67 labeling index (LI) [3 %] and nuclear
reactivity for p. 53 [4]. However, the true value of these
and other biomarkers in predicting aggressive and pro-
gressive tumor behavior in clinical practice remains
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uncertain [6, 7]. Many studies have found strong associa-
tions between Ki-67 labeling and tumor invasiveness,
tumor size and recurrence, but there is inconsistency in the
data, which may, at least in part, relate to the different
criteria and measures used to define factors such as inva-
siveness [8]. Histologic subtyping may be the best pre-
dictor of aggressive behavior once surgical biopsies have
been taken, particularly with regards to the presence of
sparse granulation in somatotroph (i.e., growth hormone-
secreting) adenomas, although subtyping into sparse versus
dense granulation does not absolutely predict aggressive-
ness and many biopsies may show intermediate charac-
teristics [7, 9, 11].
Radiological assessment of gross tumor invasiveness may
be more clinically useful, especially as it can also provide an
initial assessment of aggressive behavior obviating the need
for intraoperative biopsies. At the time of acromegaly diag-
nosis, macroadenomas (tumors[10 mm in diameter) repre-
sent approximately 80 % of GH secreting adenomas [12–14].
Although definitions of invasiveness vary, approximately
25–50 % of these macroadenomas can be defined as grossly
invasive according to the most widely used radiological or
surgical criteria (which are based on the degree of suprasellar
extension or lateral extension into the cavernous sinus) [11–
13, 15–21]. Around 50 % or more of tumors might be con-
sidered as invasive if microscopic invasion of the local dura is
employed as the criterion [22, 23].
Several other clinically-relevant factors such as young
age at diagnosis, large tumor size, and high GH secretion
have also been identified as predictors of aggressive
behavior [1]. Although pediatric cases of acromegaly are
uncommon, these cases may present with more aggressive
and larger tumors and, as such, may require more intensive
management [24, 25].
Resistance to therapy
As expected, the surgical cure rate is reduced for invasive
tumors and many may be considered inoperable, thus
necessitating other options, such as pharmacological
intervention. In general, the surgical long-term remission
rate for microadenomas is approximately 80 %, but this
decreases to less than 50 % for macroadenomas and only
25–30 % for macroadenomas classified as grossly invasive
[12, 13]. Extrasellar tumor growth, mixed tumors (GH- and
prolactin-secreting), dural invasion, tumor size, cavernous
sinus invasion, Knosp grade, and pre-operative GH and
IGF-1 levels have all been shown to be predictors of poor
surgical outcome [26, 27]. Persistent disease after surgery
might require repeat surgery, which is indicated if there is
residual tumor that is surgically accessible with a chance
for surgical cure (or with persistent mass effects on the
optic chiasm) [28], although pharmacological therapy is
indicated if this is not the case.
Resistance to pharmacological therapy may be another
manifestation of aggressive disease. In the case of
somatostatin analogs (SSAs) many factors have been
identified that predict a better response and some of these
may be worth considering before commencing therapy
[29]. For instance, older age and lower circulating GH
levels at diagnosis have all been associated with better SSA
response, and a positive acute SSA test (showing 75 % GH
reduction) may also help to predict longer-term respon-
siveness [29, 30]. Other accessible measures, such as a
hyperintense lesion on T2-weighted on MRI can predict a
poor response, as can the presence of sparse GH tumor
granulation histology [11, 29]. Various immunohisto-
chemical assays for biochemical markers, such as Ki-67 LI
(which is lower in responders), somatostatin receptor sub-
type 2 (SSTR2) expression, SSTR2/SSTR5 ratio and
especially wild-type aryl hydrocarbon receptor-interacting
protein (AIP) expression (which are all increased in
responders) may also be useful for predicting response if
biopsies are available. Recent data suggest that AIP can
predict response to SSA therapy independently of SSTR2
expression, whereas the combination of both high AIP and
high SSRT2 expression appears to be a particularly good
predictor [31, 32]. Recent evidence also suggests that SSAs
increase the expression of AIP and that it might play an
important role in their mechanism of action [33]. However,
these markers are not well validated in clinical practice and
may not be widely available due to cost restrictions [29].
Nevertheless, if available, such factors may help to inform
clinicians when making decisions about costly therapies.
The use of surgery to reduce tumor mass may help to
improve the response to SSAs treatment in those resistant
to primary SSAs therapy [34]. However, in those patients
in whom all surgical and pharmacological approaches have
failed to control the disease, radiotherapy is the only viable
option [35, 36]. That said, novel pharmacological inter-
ventions are being investigated for the treatment of par-
ticularly aggressive pituitary tumors, most notably the
orally administered alkylating agent temozolomide [37,
38]. However, experience with these agents specifically in
patients with aggressive GH-secreting adenomas is extre-
mely limited at present.
Case study: difficult choices in a patient with invasive
macroadenoma
• A 31-year-old man was referred by his cardiologist
because of acral growth and deformity of facial features
• He was noted to have hypertension and impaired
glucose tolerance 3-years earlier
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Fig. 1 Case study: post-contrast, T1-weighted MRI scans of pituitary tumor at diagnosis (a), before surgery (b) and three months after surgery
(c) (coronal left, sagittal right)
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• He also complained of fatigue and headache, arthralgia,
carpal tunnel syndrome and erectile dysfunction
• Past medical history and familial history were
unremarkable
Physical examination (initial evaluation)
• Clinical findings were hypertension, acral enlargement,
prognathism, supracilliary arch prominence, macro-
glossia, gynecomastia and thickened skin
• No visual field defects
Hormonal evaluation
• GH nadir during OGTT = 17.3 lg/L [2-h glu-
cose = 8.8 mmol/L (158 mg/dL)]
• IGF-1: 1,162 lg/L (normal 117–329 lg/L)
• T4: 103 nmol/L [8.0 lg/dL (normal 4.6–12 lg/dL)]
• TSH: 2.1 mIU/L (normal 0.3–4.1 mIU/L)
• Total testosterone: 5.5 nmol/L [159 ng/dL (normal
280–1,100 ng/dL)]
• Prolactin: 11.6 nmol/L [267 lg/L (normal 2–20 lg/L)]
• Basal cortisol/post Synacthen: 196/737 nmol/L (7/
27 lg/dL)
Pre-treatment MRI
• Post-contrast coronal T1 MRI showed 18 9 13 mm
macroadenoma in the right and inferior portion of the
pituitary, with invasion of sphenoidal sinus and erosion
of sphenoid and clivus. Tumor had hypointense signal
and normal hypophysis showed homogeneous enhance-
ment at left (Fig. 1a, b)
Diagnosis
• Acromegaly (with co-secretion of prolactin)
• Invasive macroadenoma without mass effect
• Hypogonadotrophic hypogonadism
Initial treatment
• Transsphenoidal surgery was performed (June 2009)
in an attempt to improve the response to cabergo-
line or radiation therapy (SSAs were not included
in medical insurance in Chile at the time of
diagnosis)
• Histopathology evaluation showed positive staining for
GH and prolactin, perinuclear cytokeratin staining
(densely granulated) and Ki-67 LI 4.7 %
• Predictors of poor surgical outcome were extrasellar
growth (clivus invasion) and mixed tumor
3-Months follow-up
• IGF-1 1193 lg/L (normal 115–307 lg/L)
• Random GH 10.2 lg/L
• GH nadir 8.6 lg/L
• MRI: 13 mm clivus residual tumor (Fig. 1c)
Subsequent treatment and course
• Cabergoline (3–5 mg weekly) was initiated in Septem-
ber 2009 without obtaining normalization of IGF-1
• Radiation therapy was performed in June 2010 without
normalization of IGF-1
• In July 2010, SSAs were initiated as add-on therapy to
cabergoline
• Biochemical cure was not achieved despite maximal
doses of SSA
• Currently, random GH is 1.58 lg/L (ECLIA), IGF-1
650 lg/L, hypertension and impaired glucose tolerance are
under control and no symptoms of obstructive sleep apnea
are present. The patient complains of fatigue and joint pain
Case discussion
This case provides an example of the difficult choices that
have to be made in situations where access to some ther-
apies is limited by local constraints, such as lack of reim-
bursement for specific drugs. The recommended first-line
therapy in this patient was an SSA (possibly in combina-
tion with a dopamine agonist due to prolactin co-secretion).
Due to the invasiveness of the tumor, the patient had a low
chance of surgical cure. However, due to lack of access to
SSAs at the time of diagnosis, a treatment plan had to be
made based on the available local resources—in this case,
surgery followed by cabergoline. Although the patient did
not achieve biochemical remission even after SSAs became
available, the patient has remained relatively stable. This
introduces another dilemma regarding decisions to con-
tinue a pharmacological therapy or withdraw it and put the
patient at risk of deterioration. Pressure to withdraw costly
long-term pharmacological therapy may be considerable in
areas with limited resources. Region-specific cost analyses
would be useful to justify long-term pharmacological
therapy in such situations. A further dilemma is whether to
accept stable, but suboptimal, disease control or to inten-
sify therapy further with additional cost. Guidelines rec-
ommend that patients should remain on the same dose for
at least 3 months (assuming the patient tolerates the med-
ication) to properly assess adequacy of treatment and the
need for dose titration or switching to the GH receptor
antagonist pegvisomant [39]. In the current case, intensi-
fication of pharmacological therapy beyond SSAs using the
GH receptor antagonist pegvisomant was not possible, as it
was not included in Chilean medical insurance programs.
Conclusions
Choosing the correct individually tailored therapeutic
option in a patient with acromegaly in line with current
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guidelines is a challenge, even when access to all available
surgical, pharmacological and radiotherapeutical resources
is available. This is particularly true in patients with more
aggressive disease. Failure to achieve hormonal control in
acromegaly puts patients at risk for early mortality, sug-
gesting the need for aggressive efforts to normalize hor-
mone levels [40]. In patients with aggressive, invasive
tumors, access to all available options thus becomes par-
amount. The prognosis of surgery will depend on the
characteristics of the tumor, but importantly, also on the
experience of the neurosurgeon when it comes to treat
patients with more invasive tumors [26].
The SSAs have a role as primary pharmacological
therapy and as adjuvant therapy after surgery or radiation
in patients with aggressive tumors. Newer drugs such as
GH receptor antagonists can be effective in normalization
of IGF-I in patients who do not respond to SSAs, but with a
very high cost and access to these drugs may not be pos-
sible in many areas of Latin America [41, 42]. Combina-
tion therapy with SSAs and a GH receptor antagonist may
be a safe and effective option that can help to lower doses
and reduce the costs of pharmacological treatment [43–45].
Lower cost, but less effective, medications, such as dopa-
mine agonists maybe the only pharmacological options
available in areas with restricted resources. Fortunately,
SSAs are becoming more widely available across Latin
American countries and the use of pharmacological therapy
has increased markedly over the last 10 years. Further
development of the use of biomarkers to predict aggressive
and invasive tumor behavior, as well as response to phar-
macological therapy may help clinicians to make more
informed treatment choices early and make more effective
use of available resources.
In summary, in countries with less access to experienced
pituitary surgeons and with limited access to all available
pharmacological therapies, management of aggressive GH
tumors is particularly complex and physicians may need to
make difficult choices based on available resources. Meth-
ods to improve judicious treatment selection, such as the use
of histological evaluation or development of new reliable
and accessible biomarkers predicting response to therapy,
may provide a means to optimize resource utilization.
Acknowledgments The Latin American Knowledge Network Ini-
tiative, including meetings and preparation of this supplement, was
organized and funded by Ipsen. Medical writing support was provided
by Patrick Covernton on behalf of Arsenal-CDM Paris and funded by
Ipsen. The authors were fully responsible for the concept and all
content, were involved at all stages of manuscript development, and
provided approval of the final version for submission.
Open Access This article is distributed under the terms of the
Creative Commons Attribution License which permits any use, dis-
tribution, and reproduction in any medium, provided the original
author(s) and the source are credited.
References
1. Besser GM, Burman P, Daly AF (2005) Predictors and rates of
treatment-resistant tumor growth in acromegaly. Eur J Endocrinol
153(2):187–193
2. Buchfelder M (2009) Management of aggressive pituitary ade-
nomas: current treatment strategies. Pituitary 12(3):256–260
3. Colao A, Grasso LF, Pivonello R, Lombardi G (2011) Therapy of
aggressive pituitary tumors. Expert Opin Pharmacother 12(10):
1561–1570
4. Al-Shraim M, Asa SL (2006) The 2004 World Health Organi-
zation classification of pituitary tumors: what is new? Acta
Neuropathol 111(1):1–7
5. Kontogeorgos G (2006) Predictive markers of pituitary adenoma
behavior. Neuroendocrinology 83(3–4):179–188
6. Gejman R, Swearingen B, Hedley-Whyte ET (2008) Role of Ki-
67 proliferation index and p53 expression in predicting progres-
sion of pituitary adenomas. Hum Pathol 39(5):758–766
7. Mete O, Ezzat S, Asa SL (2012) Biomarkers of aggressive
pituitary adenomas. J Mol Endocrinol 49(2):R69–R78
8. Salehi F, Agur A, Scheithauer BW, Kovacs K, Lloyd RV,
Cusimano M (2009) Ki-67 in pituitary neoplasms: a review—part
I. Neurosurgery 65(3):429–437
9. Obari A, Sano T, Ohyama K, Kudo E, Qian ZR, Yoneda A,
Rayhan N, Mustafizur Rahman M, Yamada S (2008) Clinico-
pathological features of growth hormone-producing pituitary
adenomas: difference among various types defined by cytokeratin
distribution pattern including a transitional form. Endocr Pathol
19(2):82–91
10. Kiseljak-Vassiliades K, Shafi S, Kerr JM, Phang TL, Kleinsch-
midt-DeMasters BK, Wierman ME (2012) Clinical implications
of growth hormone-secreting tumor subtypes. Endocrine 42(1):
18–28
11. Larkin S, Reddy R, Karavitaki N, Cudlip S, Wass J, Ansorge O
(2013) Granulation pattern, but not GSP or GHR mutation, is
associated with clinical characteristics in somatostatin-naive
patients with somatotroph adenomas. Eur J Endocrinol 168(4):
491–499
12. Beauregard C, Truong U, Hardy J, Serri O (2003) Long-term
outcome and mortality after transsphenoidal adenomectomy for
acromegaly. Clin Endocrinol (Oxf) 58(1):86–91
13. Minniti G, Jaffrain-Rea M-L, Esposito V, Santoro A, Tamburrano
G, Cantore G (2003) Evolving criteria for post-operative bio-
chemical remission of acromegaly: can we achieve a definitive
cure? An audit of surgical results on a large series and a review of
the literature. Endocr Relat Cancer 10(4):611–619
14. Mestron A, Webb SM, Astorga R, Benito P, Catala M, Gaz-
tambide S, Gomez JM, Halperin I, Lucas-Morante T, Moreno B,
Obiols G, de Pablos P, Paramo C, Pico A, Torres E, Varela C,
Vazquez JA, Zamora J, Albareda M, Gilabert M (2004) Epide-
miology, clinical characteristics, outcome, morbidity and mor-
tality in acromegaly based on the Spanish Acromegaly Registry
(Registro Espanol de Acromegalia, REA). Eur J Endocrinol
151(4):439–446
15. Scheithauer BW, Kovacs KT, Laws ER Jr, Randall RV (1986)
Pathology of invasive pituitary tumors with special reference to
functional classification. J Neurosurg 65(6):733–744
16. Knosp E, Steiner E, Kitz K, Matula C (1993) Pituitary adenomas
with invasion of the cavernous sinus space: a magnetic resonance
imaging classification compared with surgical findings. Neuro-
surgery 33(4):610–617
17. Thapar K, Kovacs K, Stefaneanu L, Scheithauer B, Killinger DW,
Lioyd RV, Smyth HS, Barr A, Thorner MO, Gaylinn B, Laws ER Jr
(1997) Overexpression of the growth-hormone-releasing hormone
gene in acromegaly-associated pituitary tumors. An event
S28 Pituitary (2014) 17:S24–S29
123
associated with neoplastic progression and aggressive behavior.
Am J Pathol 151(3):769–784
18. Esposito V, Santoro A, Minniti G, Salvati M, Innocenzi G,
Lanzetta G, Cantore G (2004) Transsphenoidal adenomectomy
for GH-, PRL- and ACTH-secreting pituitary tumors: outcome
analysis in a series of 125 patients. Neurol Sci 25(5):251–256
19. Saeger W, Lu¨decke DK, Buchfelder M, Fahlbusch R, Quabbe HJ,
Petersenn S (2007) Pathohistological classification of pituitary
tumors: 10 years of experience with the German Pituitary Tumor
Registry. Eur J Endocrinol 156(2):203–216
20. Kim MS, Jang HD, Kim OL (2009) Surgical results of growth
hormone-secreting pituitary adenoma. J Korean Neurosurg Soc
45(5):271–274
21. Dusek T, Kastelan D, Melada A, Baretic M, Skoric Polovina T,
Perkovic Z, Giljevic Z, Jelcic J, Paladino J, Aganovic I, Korsic M
(2011) Clinical features and therapeutic outcomes of patients
with acromegaly: single-center experience. J Endocrinol Invest
34(11):e382–e385
22. Selman WR, Laws ER Jr, Scheithauer BW, Carpenter SM (1986)
The occurrence of dural invasion in pituitary adenomas. J Neu-
rosurg 64(3):402–407
23. Meij BP, Lopes MB, Ellegala DB, Alden TD, Laws ER Jr (2002)
The long-term significance of microscopic dural invasion in 354
patients with pituitary adenomas treated with transsphenoidal
surgery. J Neurosurg 96(2):195–208
24. Dyer EH, Civit T, Visot A, Delalande O, Derome P (1994)
Transsphenoidal surgery for pituitary adenomas in children [with
discussion]. Neurosurgery 34(2):207–212
25. Abe T, Tara LA, Lu¨decke DK (1999) Growth hormone-secreting
pituitary adenomas in childhood and adolescence: features and
results of transnasal surgery. Neurosurgery 45(1):1–10
26. Kreutzer J, Vance ML, Lopes MB, Laws ER Jr (2001) Surgical
management of GH-secreting pituitary adenomas: an outcome
study using modern remission criteria. J Clin Endocrinol Metab
86(9):4072–4077
27. Jane JA Jr, Starke RM, Elzoghby MA, Reames DL, Payne SC,
Thorner MO, Marshall JC, Laws ER Jr, Vance ML (2011)
Endoscopic transsphenoidal surgery for acromegaly: remission
using modern criteria, complications, and predictors of outcome.
J Clin Endocrinol Metab 96(9):2732–2740
28. Espinosa de los Monteros AL, Gonza´lez B, Vargas G, Sosa E,
Guinto G, Mercado M (2009) Surgical reintervention in acro-
megaly: is it still worth trying? Endocr Pract 15(5):431–437
29. Gadelha MR, Kasuki L, Korbonits M (2013) Novel pathway for
somatostatin analogs in patients with acromegaly. Trends Endo-
crinol Metab 25(5):238–248
30. Colao A, Auriemma RS, Lombardi G, Pivonello R (2011)
Resistance to somatostatin analogs in acromegaly. Endocr Rev
32(2):247–271
31. Kasuki L, Colli LM, Elias PC, de Castro M, Gadelha MR (2012)
Resistance to octreotide LAR in acromegalic patients with high
SSTR2 expression: analysis of AIP expression. Arq Bras Endo-
crinol Metabol 56(8):501–506
32. Kasuki L, Vieira Neto L, Wildemberg LE, Colli LM, de Castro
M, Takiya CM, Gadelha MR (2012) AIP expression in sporadic
somatotropinomas is a predictor of the response to octreotide
LAR therapy independent of SSTR2 expression. Endocr Relat
Cancer 19(3):L25–L29
33. Chahal HS, Trivellin G, Leontiou CA, Alband N, Fowkes RC,
Tahir A, Igreja SC, Chapple JP, Jordan S, Lupp A, Schulz S,
Ansorge O, Karavitaki N, Carlsen E, Wass JA, Grossman AB,
Korbonits M (2012) Somatostatin analogs modulate AIP in
somatotroph adenomas: the role of the ZAC1 pathway. J Clin
Endocrinol Metab 97(8):E1411–E1420
34. Jallad RS, Musolino NR, Kodaira S, Cescato VA, Bronstein MD
(2007) Does partial surgical tumour removal influence the
response to octreotide-LAR in acromegalic patients previously
resistant to the somatostatin analogue? Clin Endocrinol (Oxf)
67(2):310–315
35. Jallad RS, Musolino NR, Salgado LR, Bronstein MD (2007)
Treatment of acromegaly: is there still a place for radiotherapy?
Pituitary 10(1):53–59
36. Gonza´lez B, Vargas G, Espinosa-de-los-Monteros AL, Sosa E,
Mercado M (2011) Efficacy and safety of radiotherapy in acro-
megaly. Arch Med Res 42(1):48–52
37. Syro LV, Ortiz LD, Scheithauer BW, Lloyd R, Lau Q, Gonzalez
R, Uribe H, Cusimano M, Kovacs K, Horvath E (2011) Treatment
of pituitary neoplasms with temozolomide: a review. Cancer
117(3):454–462
38. Ortiz LD, Syro LV, Scheithauer BW, Rotondo F, Uribe H, Fadul
CE, Horvath E, Kovacs K (2012) Temozolomide in aggressive
pituitary adenomas and carcinomas. Clinics (Sao Paulo) 67(Suppl
1):119–123
39. Melmed S, Colao A, Barkan A, Molitch M, Grossman AB,
Kleinberg D, Clemmons D, Chanson P, Laws E, Schlechte J,
Vance ML, Ho K, Giustina A, Acromegaly Consensus Group
(2009) Guidelines for acromegaly management: an update. J Clin
Endocrinol Metab 94(5):1509–1517
40. Sughrue ME, Chang EF, Gabriel RA, Aghi MK, Blevins LS
(2011) Excess mortality for patients with residual disease fol-
lowing resection of pituitary adenomas. Pituitary 14(3):276–283
41. Colao A, Pivonello R, Auriemma RS, De Martino MC, Bid-
lingmaier M, Briganti F, Tortora F, Burman P, Kourides IA,
Strasburger CJ, Lombardi G (2006) Efficacy of 12-month treat-
ment with the GH receptor antagonist pegvisomant in patients
with acromegaly resistant to long-term, high-dose somatostatin
analog treatment: effect on IGF-I levels, tumor mass, hyperten-
sion and glucose tolerance. Eur J Endocrinol 154(3):467–477
42. Barkan A, Bronstein MD, Bruno OD, Cob A, Espinosa-de-los-
Monteros AL, Gadelha MR, Garavito G, Guitelman M, Mangupli
R, Mercado M, Portocarrero L, Sheppard M (2010) Management
of acromegaly in Latin America: expert panel recommendations.
Pituitary 13(2):168–175
43. Jørgensen JO, Feldt-Rasmussen U, Frystyk J, Chen JW, Kris-
tensen LØ, Hagen C, Ørskov H (2005) Cotreatment of acro-
megaly with a somatostatin analog and a growth hormone
receptor antagonist. J Clin Endocrinol Metab 90(10):5627–5631
44. Feenstra J, de Herder WW, ten Have SM, van den Beld AW,
Feelders RA, Janssen JA, van der Lely AJ (2005) Combined
therapy with somatostatin analogues and weekly pegvisomant in
active acromegaly. Lancet 365(9471):1644–1646
45. Neggers SJ, de Herder WW, Janssen JA, Feelders RA, van der
Lely AJ (2009) Combined treatment for acromegaly with long-
acting somatostatin analogs and pegvisomant: long-term safety
for up to 4.5 years (median 2.2 years) of follow-up in 86 patients.
Eur J Endocrinol 160(4):529–533
Pituitary (2014) 17:S24–S29 S29
123
